Sodium stibogluconate loaded nano-deformable liposomes for topical treatment of leishmaniasis: macrophage as a target cell

References

• Abdelbary AA, Aboughaly MH. (2015). Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: application of Box–Behnken design, in vitro evaluation and in vivo skin deposition study. Int J Pharm 485:235–43.
   PubMed Web of Science ®Google Scholar
• Aboud HM, Ali AA, El-Menshawe SF. (2016). Nanotransfersomes of carvedilol for intranasal delivery: formulation, characterization and in vivo evaluation. Drug Deliv 23:2471–81.
   PubMed Web of Science ®Google Scholar
• Alving CR, Steck EA, Hanson WL. (1978). Improved therapy of experimental leishmaniasis by use of a liposome-encapsulated antimonial drug. Life Sci 22:1021–5.
   PubMed Web of Science ®Google Scholar
• Avadhani KS, Manikkath J, Tiwari M, et al. (2017). Skin delivery of epigallocatechin-3-gallate (EGCG) and hyaluronic acid loaded nano-transfersomes for antioxidant and anti-aging effects in UV radiation induced skin damage. Drug Deliv 24:61–74.
   PubMed Web of Science ®Google Scholar
• Baillie A, Coombs G, Dolan T, et al. (1986). Non-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmanial drug, sodium stibogluconate . J Pharm Pharmacol 38:502–5.
   PubMed Web of Science ®Google Scholar
• Barrett MP, Coombs GH, Mottram JC. (1999). Recent advances in identifying and validating drug targets in trypanosomes and leishmanias. Trends Microbiol 7:82–8.
   PubMed Web of Science ®Google Scholar
• Bavarsad N, Bazzaz BSF, Khamesipour A, et al. (2012). Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice. Acta Trop 124:33–41.
   PubMed Web of Science ®Google Scholar
• Borborema SET, Schwendener RA, Junior JO, et al. (2011). Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages. Int J Antimicrob Agents 38:341–7.
   PubMed Web of Science ®Google Scholar
• Cevc G. (1996). Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit Rev Ther Drug Carrier Syst 13:257–388.
   PubMed Web of Science ®Google Scholar
• Cevc G, Schätzlein A, Richardsen H. (2002). Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements. Biochim Biophys Acta 1564:21–30.
   PubMed Web of Science ®Google Scholar
• Chaudhary H, Kohli K, Kumar V. (2013). Nano-transfersomes as a novel carrier for transdermal delivery. Int J Pharm 454:367–80.
   PubMed Web of Science ®Google Scholar
• Cipolla D, Wu H, Eastman S, et al. (2014). Development and characterization of an in vitro release assay for liposomal ciprofloxacin for inhalation. J Pharm Sci 103:314–27.
   Web of Science ®Google Scholar
• Dar MJ, Ali H, Khan A, et al. (2017). Polymer-based drug delivery: the quest for local targeting of inflamed intestinal mucosa. J Drug Target 25:582–96.
   PubMed Web of Science ®Google Scholar
• Draize JH, Woodard G, Calvery HO. (1944). Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther 82:377–90.
   Web of Science ®Google Scholar
• Dreher F, Walde P, Walther P, et al. (1997). Interaction of a lecithin microemulsion gel with human stratum corneum and its effect on transdermal transport. J Control Release 45:131–40.
   Web of Science ®Google Scholar
• Dubey V, Mishra D, Nahar M, et al. (2007). Vesicles as tools for the modulation of skin permeability. Expert Opin Drug Deliv 4:579–93.
   PubMed Web of Science ®Google Scholar
• El Maghraby GM, Barry BW, Williams AC. (2008). Liposomes and skin: from drug delivery to model membranes. Eur J Pharm Sci 34:203–22.
   PubMed Web of Science ®Google Scholar
• El Maghraby GM, Williams AC, Barry BW. (2001). Skin delivery of 5-fluorouracil from ultradeformable and standard liposomes in-vitro . J Pharm Pharmacol 53:1069–77.
   PubMed Web of Science ®Google Scholar
• El Zaafarany GM, Awad GA, Holayel SM, et al. (2010). Role of edge activators and surface charge in developing ultradeformable vesicles with enhanced skin delivery. Int J Pharm 397:164–72.
   PubMed Web of Science ®Google Scholar
• El-Samaligy M, Afifi N, Mahmoud E. (2006). Increasing bioavailability of silymarin using a buccal liposomal delivery system: preparation and experimental design investigation. Int J Pharm 308:140–8.
   PubMed Web of Science ®Google Scholar
• Espuelas S. (2015). Conventional formulations and emerging delivery systems for the topical treatment of cutaneous leishmaniasis. Ther Deliv 6:101–3.
   PubMed Web of Science ®Google Scholar
• Frézard F, Demicheli C. (2010). New delivery strategies for the old pentavalent antimonial drugs. Expert Opin Drug Deliv 7:1343–58.
   PubMed Web of Science ®Google Scholar
• Frézard F, Michalick M, Soares C, et al. (2000). Novel methods for the encapsulation of meglumine antimoniate into liposomes. Braz J Med Biol Res 33:841–6.
   PubMed Web of Science ®Google Scholar
• Garnier T, Croft SL. (2002). Topical treatment for cutaneous leishmaniasis. Curr Opin Investig Drugs 3:538–44.
   PubMedGoogle Scholar
• Gupta PN, Mishra V, Rawat A, et al. (2005). Non-invasive vaccine delivery in transfersomes, niosomes and liposomes: a comparative study. Int J Pharm 293:73–82.
   PubMed Web of Science ®Google Scholar
• Hadgraft J, Pugh WJ. (1998). The selection and design of topical and transdermal agents: a review. J Investig Dermatol Symp Proc 3:131–5.
   PubMedGoogle Scholar
• Honary S, Zahir F. (2013). Effect of zeta potential on the properties of nano-drug delivery systems – a review (Part 2). Trop J Pharm Res 12:265–73.
   Web of Science ®Google Scholar
• Jain S, Jain P, Umamaheshwari RB, Jain NK. (2003). Transfersomes – a novel vesicular carrier for enhanced transdermal delivery: development, characterization, and performance evaluation. Drug Dev Ind Pharm 29:1013–26.
   PubMed Web of Science ®Google Scholar
• Jain S, Puri R. (2014). Development, characterization and in vivo localization study of topical 5-fluorouracil gels: a comparative study with conventional formulation. Curr Drug Deliv 11:401–14.
   PubMed Web of Science ®Google Scholar
• Kashani MN, Firooz A, Eskandari SE, et al. (2007). Evaluation of meglumine antimoniate effects on liver, kidney and pancreas function tests in patients with cutaneous leishmaniasis. Eur J Dermatol 17:513–5.
   PubMed Web of Science ®Google Scholar
• Kaur L, Jain SK, Singh K. (2015). Vitamin E TPGS based nanogel for the skin targeting of high molecular weight anti-fungal drug: development and in vitro and in vivo assessment. RSC Adv 5:53671–86.
   Web of Science ®Google Scholar
• Khamesipour A, Khatemi A, Sharifi I, et al. (2010). Comparison of the efficacy of weekly vs. twice a week intralesional injections of meglumine antimoniate in the treatment of anthroponotic cutaneous leishmaniasis: a randomized clinical trial. J Dermatol Cosmet 1:155–61.
   Google Scholar
• Kumar R, Bumb RA, Ansari NA, et al. (2007). Cutaneous leishmaniasis caused by Leishmania tropica in Bikaner, India: parasite identification and characterization using molecular and immunologic tools. Am J Trop Med Hyg 76:896–901.
   PubMed Web of Science ®Google Scholar
• Mir-Palomo S, Nácher A, Díez-Sales O, et al. (2016). Inhibition of skin inflammation by baicalin ultradeformable vesicles. Int J Pharm 511:23–9.
   PubMed Web of Science ®Google Scholar
• Montanari J, Maidana C, Esteva MI, et al. (2010). Sunlight triggered photodynamic ultradeformable liposomes against Leishmania braziliensis are also leishmanicidal in the dark. J Control Release 147:368–76.
   PubMed Web of Science ®Google Scholar
• Moosavian Kalat SA, Khamesipour A, Bavarsad N, et al. (2014). Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice. Exp Parasitol 143:5–10.
   PubMed Web of Science ®Google Scholar
• Nahar M, Jain NK. (2009). Preparation, characterization and evaluation of targeting potential of amphotericin B-loaded engineered PLGA nanoparticles. Pharm Res 26:2588.
   PubMed Web of Science ®Google Scholar
• Nieto J, Alvar J, Mullen A, et al. (2003). Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals. Antimicrob Agents Chemother 47:2781–7.
   PubMed Web of Science ®Google Scholar
• Nwaka S, Hudson A. (2006). Innovative lead discovery strategies for tropical diseases. Nat Rev Drug Discov 5:941.
   PubMed Web of Science ®Google Scholar
• Obata Y, Utsumi S, Watanabe H, et al. (2010). Infrared spectroscopic study of lipid interaction in stratum corneum treated with transdermal absorption enhancers. Int J Pharm 389:18–23.
   PubMed Web of Science ®Google Scholar
• Oliveira LF, Schubach AO, Martins MM, et al. (2011). Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. Acta Trop 118:87–96.
   PubMed Web of Science ®Google Scholar
• Pathak K, Sharma V, Sharma M. (2016). Optimization, in vitro cytotoxicity and penetration capability of deformable nanovesicles of paclitaxel for dermal chemotherapy in Kaposi sarcoma. Artif Cells Nanomed Biotechnol 44:1671–83.
   PubMed Web of Science ®Google Scholar
• Reithinger R, Dujardin J-C, Louzir H, et al. (2007). Cutaneous leishmaniasis. Lancet Infect Dis 7:581–96.
   PubMed Web of Science ®Google Scholar
• Sankhyan A, Pawar PK. (2013). Metformin loaded non-ionic surfactant vesicles: optimization of formulation, effect of process variables and characterization. DARU J Pharm Sci 21:7.
   Web of Science ®Google Scholar
• Singh S, Verma D, Mirza MA, et al. (2017). Development and optimization of ketoconazole loaded nano-transfersomal gel for vaginal delivery using Box–Behnken design: In vitro, ex vivo characterization and antimicrobial evaluation. J Drug Deliv Sci Technol 39:95–103.
   Web of Science ®Google Scholar
• Tempone AG, Perez D, Rath S, et al. (2004). Targeting Leishmania (L.) chagasi amastigotes through macrophage scavenger receptors: the use of drugs entrapped in liposomes containing phosphatidylserine. J Antimicrob Chemother 54:60–8.
   PubMed Web of Science ®Google Scholar
• Touitou E, Dayan N, Bergelson L, et al. (2000). Ethosomes – novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Control Release 65:403–18.
   PubMed Web of Science ®Google Scholar
• Verma DD, Verma S, Blume G, et al. (2003). Particle size of liposomes influences dermal delivery of substances into skin. Int J Pharm 258:141–51.
   PubMed Web of Science ®Google Scholar
• Want MY, Islammudin M, Chouhan G, et al. (2017). Nanoliposomal artemisinin for the treatment of murine visceral leishmaniasis. Int J Nanomedicine 12:2189.
   PubMed Web of Science ®Google Scholar
• World Health Organization. (1990). Control of the leishmaniasis: report of a meeting of the WHO Expert Committee on the Control of Leishmaniasis.
   Google Scholar
• World Health Organization. (1991). Basic laboratory methods in medical parasitology: report of a WHO Expert Committee.
   Google Scholar